Previous 10 | Next 10 |
home / stock / meso / meso articles
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), Chief Executive Silviu Itescu provided a corporate update...
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of XPeng Inc. (NYSE:XPEV) rose sharply during ...
U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday'...
U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Tuesday. Shares of Medifast, Inc. (NYSE:MED) fe...
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily ...
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday...
Shares of Nucor Corporation (NYSE:NUE) fell sharply during Tuesday's session after the company reported worse-than-expected quarterly financia...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
U.S. stocks were lower, with the Dow Jones index falling over 50 points on Wednesday. Shares of United Airlines Holdings, Inc. (NASDAQ: UAL) rose ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today it has resubmitted its BLA for approval of Ryoncil ® (remestemcel-L) in the treatment of children with SR-aGVHD....
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil ® (remestemcel-L) in the treat...